


# HEMORRHAGIC STROKE



**Dr. Claire Karekezi**

# Worldwide statistics

- WHO: **15 million** people suffer a stroke each year;
- **5 million die**, about **5 million** permanently disabled.
- High blood pressure contributes to over **12.7 million strokes** worldwide
- Risk of stroke in blacks: almost **twice** that of whites
- In HIC incidence of stroke declining due to efforts to lower blood pressure and reduce smoking
- Overall rate of stroke high due to the **aging** of the population

# ICH by numbers

- Result of a rupture of blood vessel in the brain
- Accounts for **10-15%** of all cerebrovascular accidents
- **2 million** strokes every year worldwide
- Rise of admissions in the past 10 years by **18%**
- Prognosis is poor: estimated mortality
  - **30% at 7 days**
  - **60% at 1 year**
  - **82% at 10 years**
  - **>90% at 16 years**

# RISK FACTORS

## NON-MODIFIABLE

- Age
- Sex
- Race
  - Asians > Afr. Amer. > White
- Genetics:
  - Cerebral amyloid angiopathy, coagulation disorders

## MODIFIABLE

- HTN
- Cerebral amyloid angiopathy
- Cholesterol
- Anti-coagulation
- Anti-platelets
- High EtOH intake
- Smoking
- DM
- Microbleeds
- Dialysis
- Drug-Induced (e.g. cocaine, amphetamines)

# Mechanisms

Traumatic	Non-traumatic
Head injury	Uncontrolled hypertension
	Anticoagulant therapy
	Platelet and coagulation disorders
	Vascular malformations
	Brain tumors
	Cerebral amyloid angiopathy
	Drug-induced: cocaine, amphetamines

# Hypertension and ICH

- **Most important risk factor (>70% of lry ICH)**
- Bifurcation of small penetrating arteries (50–700  $\mu\text{m}$  diameter)
- **Atherosclerosis**
  - Lipid deposition, layering of platelet and fibrin aggregates, breakage of elastic lamina, atrophy and fragmentation of smooth muscle, dissections, and granular or vesicular cellular degeneration
- **Charcot and Bouchard aneurysm**
  - Fibrinoid necrosis of the subendothelium  $\rightarrow$  focal dilatations  $\rightarrow$  rupture of microaneurysm





# PHYSIOPATHOLOGY

Usually occurs spontaneously  
Caused by vascular rupture with  
bleeding into brain

- Mass effect can further cause  
bleeding and hematoma expansion  
from neighboring vessels

Hematoma growth over several  
hours following presentation of  
symptoms is common (30-40%)  
Hemorrhages commonly occurs  
at the basal ganglia, thalamus,  
pons, or cerebellum



Chronic hypertension → structural wall changes of small arteries and arterioles in the brain

- Fibrinoid necrosis
- Charcot-Bouchard aneurysms

Idiopathic hypertension (acute) → usually younger patients with history of drug abuse

- Amphetamine, cocaine
- May occur minutes to hours after drug use

Vascular malformations


- Arteriovenous malformations (AVM): failure of formation of capillary beds
- Saccular (berry): results from developmental weakness of arteriole walls

Hemorrhages can cause compression to nearby brain tissues


- May result in brain tissue inflammation and edema



## Intracerebral hemorrhage in the brain




# SITES



## Basal ganglia 35-40%


- Ascending lenticulostriate branches of MCA
- Wide spectrum of severity extending to coma and decerebrate rigidity
- Ventricular extension carries very poor prognosis






## Lobar hemorrhage 25%

- Penetrating cortical branches of ACA, MCA, & PCA
- Peripheral location  $\therefore$  lower frequency of coma
- Lower mortality
- Better functional outcome






## Thalamus 10-15%


- Ascending thalamogeniculate branches of PCA
- Abrupt hydrocephalus from aqueductal obstruction from intraventricular clot
- Responds to ventriculostomy





## Pons 5%

- Paramedian branches of the basilar artery
- Bilateral carries very poor prognosis (coma, quadriplegia, decerebrate posturing, horizontal ophthalmoplegia, pinpoint reactive pupils)



## Cerebellum 5-10%

- Penetrating branches of the PICA, AICA, SCA
- Abrupt onset vertigo, h/a, n/v, inability to walk in absence of weakness
- Ipsilateral ataxia, horizontal gaze palsy, peripheral facial palsy
- Unpredictable deterioration to coma

# Anticoagulation associated ICH

- Warfarin is a Vit K antagonist
  - Inhibits biosynthesis of factors II, VII, IX, X
  - Maximum effect is 48 hrs after administration
- Incidence of ICH is 0.3-0.6% per year in patients on chronic warfarin anticoagulation
- Risk factors
  - Age, chronic hypertension, CAA, leukoaraiosis
  - Elevation of INR (doubled risk for 0.5 ↑ above 4.5!)
- INR correlated with hematoma expansion and prognosis

# Clinical features

- Features of intracranial hypertension
  - Headache, vomiting, decreased LOC
  - Correlated with hematoma size and prognosis
  - Progressive over time
  - Seizures in lobar ICH
- Focal neurological deficits depending on the location of ICH

# Think FAST

**ACT FAST** at the First Sign of **STROKE**



[www.strokemn.org](http://www.strokemn.org)

**Minnesota Stroke Association**  
Chapter of the National Stroke Association 

The infographic is a vertical strip with a light beige background. It features four rows, each corresponding to a letter of the FAST acronym. 1. 'Face': Illustration of a man's face. Text: 'Does the face look uneven? Ask them to smile.' 2. 'Arm': Illustration of a woman's arm. Text: 'Does one arm drift down? Ask them to raise both arms.' 3. 'Speech': Illustration of a woman speaking. Text: 'Does their speech sound strange? Ask them to repeat a phrase.' 4. 'Time': Illustration of a hand holding a phone, a clock, and an ambulance. Text: 'Every second brain cells die. Call 9-1-1 at any sign of stroke!' To the right of these rows, there is a larger text block: 'Is it a stroke? Check these signs FAST!' and 'Call 9-1-1 at any sign of stroke.' At the top right, there is a small graphic of a 'FAST' sign and a phone.



Eye Opening (E)	Verbal Response (V)	Motor Response (M)
4 = spontaneous 3 = to voice 2 = to pain 1 = none	5 = normal conversation 4 = disoriented conversation 3 = words, but not coherent 2 = no words, only sounds 1 = none	6 = normal 5 = localized to pain 4 = withdraws to pain 3 = decorticate posture <sup>α</sup> 2 = decerebrate <sup>β</sup> 1 = none


Assessment:

- Severe: GCS 3-8 (cannot score lower than a 3)
- Moderate: GCS 9-12
- Mild: GCS 13-15

# INVESTIGATION

Test	Results
Head CT	<ul style="list-style-type: none"><li>• Differentiates hemorrhagic from ischemic stroke</li></ul>
ECG	<ul style="list-style-type: none"><li>• Signs of myocardial ischemia, large inverted T waves</li></ul>
Labs	<ul style="list-style-type: none"><li>• <u>Chem panel</u> – r/o conditions that have similar presentation</li><li>• <u>CBC</u> – thrombocytopenia</li><li>• <u>PT/PTT</u> – w/o coagulopathy as cause</li></ul>
MRI	<ul style="list-style-type: none"><li>• r/o aneurysm or arteriovenous malformation as a cause of bleeding</li></ul>
CT angiography	<ul style="list-style-type: none"><li>• Recommended in all patients &lt;45 years of age and in all patients with intracerebral hemorrhage in lobar brain regions</li></ul>
Invasive angiography	

# Head CT



Normal CT Scan  
Slice of Brain




Intracerebral Hemorrhage  
(bright white area)  
CT Scan Slice of Brain



# Hematoma expansion

- Hematoma enlargement
  - >70% have hematoma enlargement w/in 3 hrs of symptom onset; 1/3 clinically significant
  - Most occur within 3 hrs, can be up to 12 hrs
  - Independent predictor of worse outcome & ↑ mortality



Mainstay of ICH therapy is to treat the underlying cause when possible

General treatment approach is always patient specific depending on clinical condition



# INITIAL MANAGEMENT

- Stabilization of Vital Signs
  - Neurological exam
- Supportive care
  - Management of seizures
- Blood pressure control
- Fever control
- Anticoagulation correction
- Blood sugar control
- Surgical/Invasive Interventions

- Antihypertensive agents for ICH have not been compared in controlled trials
- Suggested agents:
  - Labetolol
  - Enalapril
- For refractory hypertension:
  - Nicardipine
  - Hydralazine
  - Nitroprusside
    - Can lead to elevated ICP

- Goal SBP to  $< 180$  mm Hg within 1 hour is and maintain for next 24 hours
  - INTERACT study suggests more aggressive therapy with goal SBP  $< 140$  mm Hg leads to better outcomes

# Acute management of BP

## PROs

- ↑ BP associated with poor outcome
- ↑ risk of hematoma enlargement
- ↑ edema formation
- Systemic damage (e.g. ongoing cardiac ischemia)

## CONs

- Chronic HTN shifts cerebral auto-regulatory curve to the right
- ↑ ICP may require ↑ BP to maintain CPP
- Previously thought to induce ischemic damage to the at risk penumbra

# Acute management of BP

Condition	Treatment Approach
SBP > 200 mmHg or MAP is 150 mmHg	Aggressive ↓BP with continuous IV infusion, with frequent BP monitoring Q5 min
SBP is 180 mmHg or MAP is 130 mmHg and there is the <i>possibility</i> of ↑ICP	Monitor ICP and ↓BP using intermittent or continuous IV meds while maintaining cerebral perfusion pressure 60 mmHg
SBP is 180 mmHg or MAP is 130 mmHg and there is <i>no evidence</i> of ↑ICP	Modest ↓BP (eg, MAP of 110 mm Hg or target BP of 160/90 mm Hg) using intermittent or continuous IV meds to control BP and clinically reexamine the patient Q15 min



- Elevate head of bed to 30 degrees
  - Analgesia and sedation as needed
- Aggressive therapies:
  - Osmotic therapy
    - Mannitol
      - RCT failed to demonstrated difference in disability or death at 3 months
    - Hypertonic Saline
    - Barbituate anesthesia
  - Hyperventilation and glucocorticoids not recommended

- High blood glucose on admission predicts an increased risk of mortality and poor outcome in patients with and without diabetes and ICH
  - Use of insulin is controversial. Hypoglycemia should be avoided.

- CSF drainage may be appropriate in setting of obstructive hydrocephalus
  - High rates of complication : bacterial meningitis
- Endoscopic hematoma Evacuation
  - May improve long-term prognosis

- Use of platelet transfusions in ICH patients with a history of antiplatelet use is unclear
  - May be indicated for patients with severe thrombocytopenia
- Intermittent pneumatic compression recommended
- May consider low dose SQ LMWH or UFH for prevention of DVT
  - After 1 to 4 days from onset with lack of mobility



# Approach to ICP management

## CSF volume

- Mannitol or hypertonic solution
- External CSF drainage
- Ventricular catheter
- Ventriculo - peritoneal or atrial shunt
- Lumbar drain
- Serial lumbar punctures

## Brain volume

- Mannitol or hypertonic saline
- Decompressive craniectomy
- Resection of tumor or other mass lesion

## Seizure Control

## Blood volume

- Mannitol or hypertonic saline
- Hyperventilation
- Hypothermia
- Head elevation, neutral neck position
- Deep propofol or barbiturate sedation ± paralysis

# Decompressive Craniectomy

- Surgical removal of cranial bone flap to relieve intracranial pressure
- Useful in large ischemic CVA with profound edema
- Role in traumatic brain injury still needs to be established

# Complications

- Aspiration pneumonia
  - Stroke-related dysphagia
  - Therapy: dysphagia/swallow evaluation before moving to PO status
- Hydrocephalus
  - Elevation of CSF pressure of the brain
  - Cognitive impairment, urinary/fecal incontinence
  - Therapy: external ventricular drain placement, ventriculoperitoneal shunt
- Seizures
  - May complicate treatment for ICH; higher risk in cortical bleeding
  - Therapy: benzodiazapines, phenytoin, fosphenytoin

## ■ Delirium

- May be fairly common following ICH
- Therapy: supportive care, sedatives and neuromuscular blockade, careful hemodynamic management

## ■ Deep venous thrombosis

- Motor weakness, venous stasis
- Therapy: anticoagulation, inferior vena cava filter

## ■ Infection

- Nosocomial pneumonia, urinary tract infection, cellulitis from pressure sores
- Therapy: appropriate broad-spectrum coverage, then narrowing for cultured organisms



# Preventive Measures

- Lifestyle modifications:
  - smoking cessation, refrain from alcohol, diet/exercise, weight control
- Control blood pressure
- Control LDL
- Clot prevention: Warfarin, Aggrenox, Plavix

# Recurrence: Risk Factors

- Lobar location of initial ICH
- Uncontrolled hypertension
- Older age
- Ongoing anticoagulation
- Apolipoprotein E epsilon 2 or epsilon 4 alleles
- Greater number of microbleeds on MRI

- Monitoring by appropriate specialists for rehabilitation
  - Physical therapist, occupational therapist, speech and language pathologist
- Strict management of HTN
- Antiplatelet/anticoagulation therapy

# Conclusions

- ICH has an increasing incidence, but continues to have a very poor prognosis
- Hypertension is a major risk factor
- Acute BP reduction of 15-20% is safe



# References

- Goldstein, JN et al. Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage, *Neurology* 2007;68:889–894
- Qureshi AI et al. Intracerebral hemorrhage, *Lancet* 2009; 373: 1632–44
- Wada, R et al. CT Angiography “Spot Sign” Predicts Hematoma Expansion in Acute Intracerebral Hemorrhage, *Stroke* 2007;38:1257-1262
- Diringer MN. Update on intracerebral hemorrhage, *AAN Continuum*, 2009
- Kincaid MS and Lam AM, Monitoring and managing ICP, *AAN Continuum*, 2006